Diagnosis of antibody-mediated rejection in cardiac transplantation: A call for standardization

Current Opinion in Organ Transplantation

Volumn 15, Issue 6, 2010, Pages 769-773

  Tan, Carmela D ^a   Rodriguez, E Rene ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

accommodation; antibody mediated rejection; cardiac transplantation; complement

Indexed keywords

ALLOANTIBODY; BIOLOGICAL MARKER; CD3 ANTIGEN; CD4 ANTIGEN; LEUKOCYTE ANTIGEN;

ANTIBODY MEDIATED GRAFT REJECTION; BIOPSY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL PRACTICE; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; PREDICTOR VARIABLE; REVIEW; RISK ASSESSMENT; STANDARDIZATION; SYMPTOM;

ANTIBODIES; COMPLEMENT C3D; COMPLEMENT C4B; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; ISOANTIBODIES; PEPTIDE FRAGMENTS;

EID: 78649677065     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834016e4     Document Type: Review

References (34)

1. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications 4. J Heart Transplant 1989; 8:430-443.
2. Lones MA, Czer LS, Trento A, et al. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant 1995; 14:151-162.
3. Bonnaud EN, Lewis NP, Masek MA, et al. Reliability and usefulness of immunofluorescence in heart transplantation. J Heart Lung Transplant 1995; 14:163-171.
4. Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005; 5:2778-2785.
5. Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009; 9:2075-2084.
6. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033-1041.
7. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25:153-159.
8. Hammond ME, Stehlik J, Snow G, et al. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J Heart Lung Transplant 2005; 24:2015-2021.
9. Kucirka LM, Maleszewski JJ, Segev DL, et al. Survey of North American pathologist practices regarding antibody-mediated rejection in cardiac trans-plant biopsies. Cardiovasc Pathol 2010. [Epub ahead of print]
10. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989; 8:430-443.
11. Chantranuwat C, Qiao JH, Kobashigawa J, et al. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immuno-histochem Mol Morphol 2004; 12:166-171.
12. Miller D V, Roden A C, Gamez J, et al. Deposition of C4d in cardiacallografts: a comparative study of immunofluorescence and immunoperoxidase methods. Arch Pathol Lab Med (in press).
13. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banffworking groups. Am J Trans-plant 2010; 10:464-471.
14. Kfoury A G, Renlund DG, Snow G L, et al. Aclinical correlation studyofseverity of antibody-mediated rejection and cardiovascular mortality in heart trans-plantation. J Heart Lung Transplant 2009; 28:51-57.
15. Gupta S, Mitchell JD, Lavingia B, et al. Utility of routine immunofluorescence staining for C4d in cardiac transplant recipients. J Heart Lung Transplant 2009; 28:776-780.
16. Kfoury AG, Hammond ME, Snow GL, et al. Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2007; 26:1264-1269.
17. Ho EK, Vlad G, Colovai AI, et al. Alloantibodies in heart transplantation. Hum Immunol 2009; 70:825-829.
18. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70:605-609.
19. Zeevi A, Lunz JG III, Shapiro R, et al. Emerging role of donor-specific antihuman leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol 2009; 70:645-650.
20. Leffell MS, Zachary AA. Antiallograft antibodies: relevance, detection, and monitoring. Curr Opin Organ Transplant 2010; 15:2-7.
21. Kobashigawa J, Mehra M, West L, et al. Reportfrom aconsensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Trans-plant 2009; 28:213-225.
22. Suarez-Alvarez B, Lopez-Vazquez A, Gonzalez MZ, et al. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 2007; 7:1842-1848.
23. Kauke T, Kaczmarek I, Dick A, et al. Anti-MICA antibodies are related to adverse outcome in heart transplant recipients. J Heart Lung Transplant 2009; 28:305-311.
24. Alvarez-Marquez A, Aguilera I, Blanco RM, et al. Positive association of anticytoskeletal endothelial cell antibodies and cardiac allograft rejection. Hum Immunol 2008; 69:143-148.
25. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71:886-892.
26. Smith JD, Brunner VM, Jigjidsuren S, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant 2009; 9:1912-1919.
27. Tan CD, Sokos GG, Pidwell DJ, et al. Can C4d staining alone predict acute antibody-mediated rejection in heart transplants? J Heart Lung Transplant 2009; 28:S114-115.
28. Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant 2009; 28:781-784.
29. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection afterhearttransplantation predicts pooroutcomes. J Heart Lung Transplant 2009; 28:417-422.
30. Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr Opin Organ Transplant2008; 13:165-170.
31. Williams JM, Holzknecht ZE, Plummer TB, et al. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation 2004; 78:1471-1478.
32. Haas M. The significance of C4d staining with minimal histologic abnormalities. Curr Opin Organ Transplant 2010; 15:21-27.
33. Ding JW,Zhou T, Ma L, et al. Expression ofcomplement regulatory proteins in accommodated xenografts induced by antialpha-Gal IgG1 in a rat-to-mouse model. Am J Transplant 2008; 8:32-40.
34. Eckman PM, Thorsgard M, Maurer D, et al. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Clin Transpl 2009; 1:475-478.